To place an obituary, please include the information from the obituary checklist below in an email to obits@pioneerpress.com. There is no option to place them through our website. Feel free to contact our obituary desk at 651-228-5263 with any questions.
General Information:
Your full name,
Address (City, State, Zip Code),
Phone number,
And an alternate phone number (if any)
Obituary Specification:
Name of Deceased,
Obituary Text,
A photo in a JPEG or PDF file is preferable, TIF and other files are accepted, we will contact you if there are any issues with the photo.
Ad Run dates
There is a discount for running more than one day, but this must be scheduled on the first run date to apply.
If a photo is used, it must be used for both days for the discount to apply, contact us for more information.
Policies:
Verification of Death:
In order to publish obituaries a name and phone number of funeral home/cremation society is required. We must contact the funeral home/cremation society handling the arrangements during their business hours to verify the death. If the body of the deceased has been donated to the University of Minnesota Anatomy Bequest Program, or a similar program, their phone number is required for verification.
Please allow enough time to contact them especially during their limited weekend hours.
A death certificate is also acceptable for this purpose but only one of these two options are necessary.
Guestbook and Outside Websites:
We are not allowed to reference other media sources with a guestbook or an obituary placed elsewhere when placing an obituary in print and online. We may place a website for a funeral home or a family email for contact instead; contact us with any questions regarding this matter.
Obituary Process:
Once your submission is completed, we will fax or email a proof for review prior to publication in the newspaper. This proof includes price and days the notice is scheduled to appear.
Please review the proof carefully. We must be notified of errors or changes before the notice appears in the Pioneer Press based on each day’s deadlines.
After publication, we will not be responsible for errors that may occur after final proofing.
Online:
Changes to an online obituary can be handled through the obituary desk. Call us with further questions.
Payment Procedure:
Pre-payment is required for all obituary notices prior to publication by the deadline specified below in our deadline schedule. Please call 651-228-5263 with your payment information after you have received the proof and approved its contents.
Credit Card: Payment accepted by phone only due to PCI (Payment Card Industry) regulations
EFT: Check by phone. Please provide your routing number and account number.
Cash: Accepted at our FRONT COUNTER Monday – Friday from 8:00AM – 3:30PM
Rates:
The minimum charge is $162 for the first 10 lines.
Every line after the first 10 is $12.20.
If the ad is under 10 lines it will be charged the minimum rate of $162.
On a second run date, the lines are $8.20 per line, starting w/ the first line.
For example: if first run date was 20 lines the cost would be $164.
Each photo published is $125 per day.
For example: 2 photos in the paper on 2 days would be 4 photo charges at $500.
Deadlines:
Please follow deadline times to ensure your obituary is published on the day requested.
Hours
Deadline (no exceptions)
Ad
Photos
MEMORIAM (NON-OBITUARY) REQUEST
Unlike an obituary, Memoriam submissions are remembrances of a loved one who has passed. The rates for a memoriam differ from obituaries.
Please call or email us for more memoriam information
Please call 651-228-5280 for more information.
HOURS: Monday – Friday 8:00AM – 5:00PM (CLOSED WEEKENDS and HOLIDAYS)
Please submit your memoriam ad to memoriams@pioneerpress.com or call 651-228-5280.
By MATTHEW PERRONE, AP Health Writer
WASHINGTON (AP) — Federal officials have approved another generic version of the abortion pill mifepristone, a regulatory formality that quickly triggered pushback from anti-abortion groups aligned with the Trump administration.
Drugmaker Evita Solutions announced on its website that the Food and Drug Administration signed off on its low-cost form of the pill, which is approved to end pregnancies through 10 weeks.
Students for Life Action, which opposes abortion, in a statement Thursday called the approval “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”
The criticism comes as Republican President Donald Trump’s top health officials, including Health Secretary Robert F. Kennedy Jr., face growing pressure from abortion opponents to reevaluate mifepristone, which was approved 25 years ago and has repeatedly been deemed safe and effective by FDA scientists.
In a letter to Republican attorneys general last month, Kennedy and FDA Commissioner Dr. Marty Makary pledged to conduct a full review of the drug’s safety.
The FDA approved the original version of mifepristone in 2000 and gradually eased access over time. That included approving the first generic pill, from drugmaker GenBioPro, in 2019.
In 2021, the FDA under Democratic President Joe Biden permitted online prescribing and mail-order delivery of the drug, greatly expanding access. Abortion opponents have been fighting the change ever since.
Approval of generic drugs is typically a rote process at the FDA, with multiple copycat versions usually approved after the patent on the original drug expires. In most cases, generic drugmakers only need to show that they’re drug matches the ingredients and formula developed by the original drugmaker.
The FDA typically approves such applications within 10 months. But filing documents posted to the FDA’s website show that Evita Solutions filed its application to market mifepristone four years ago.
The company did not immediately respond to requests for comment.
On its website, Evita states that it “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care.”
Approval of a second generic is unlikely to affect access to the pill, which is typically taken with another drug, misoprostol. The combination accounts for roughly two-thirds of all U.S. abortions. Mifepristone dilates the cervix and blocks the hormone progesterone, while misoprostol causes the uterus to cramp and contract.
Access to mifepristone is restricted across large sections of the country because of state laws that ban abortion — including medication abortion — or impose separate restrictions on the drug’s use. Those laws are subject to a number of ongoing lawsuits that are winding their way through the legal system
Restrictions on the pill are not supported by most major medical societies, including the American Medical Association.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Originally Published: October 2, 2025 at 2:52 PM CDT